
Adamas Pharma higher after positive Gocovri trial data
Adamas Pharmaceuticals (NASDAQ:ADMS) has published trial data indicating its Gocovri has maintained its treatment effect on motor complications for at leas
Adamas Pharmaceuticals (NASDAQ:ADMS) has published trial data indicating its Gocovri has maintained its treatment effect on motor complications for at leas
On a preliminary basis, Adamas Pharmaceuticals ([[ADMS]] +10.3%) expects Gocovri (amantadine) sales in Q4 and 2019 to be ~$16.3M (+23%) and ~$54.6M (+61%),
Adamas Pharmaceuticals ([[ADMS]] +5.5%) has settled its patent infringement litigation with Novartis' ([[NVS]] +0.1%) Sandoz unit related to Parkinson's di
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Consumer Services, Utilities and Basic Materials sectors propelled shares higher. At the close in NYSE,...
Investing.com – U.S. equities were higher at the close on Monday, as gains in the Technology, Healthcare and Consumer Services sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Basic Materials, Industrials and Oil & Gas sectors propelled shares lower. At the close in NYSE, the Dow...
Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Telecoms, Utilities and Consumer Goods sectors propelled shares lower. At the close in NYSE, the Dow Jones...
Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Telecoms, Oil & Gas and Consumer Services sectors propelled shares higher while losses in the Healthcare,...
* Futures up: Dow 45 pts, S&P 6.75 pts, Nasdaq 19.75 ptsBy Sruthi ShankarAug 25 (Reuters) - U.S. stock index futures were higher on Friday as investors await Fed Chair Janet...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.